Movement Alert｜Boston Scientific Falls 3.03% in Regular Trading, Full-Year Guidance Cut and Multiple Analyst Target Reductions Continue to Weigh

Market Focus08-05

On August 5, Boston Scientific declined 3.03% in regular trading, trading at $47.605 per share, with turnover of $182 million.

The decline reflects continued pressure from the company's lowered full-year guidance and a wave of analyst target price cuts. Boston Scientific reported Q2 adjusted EPS of $0.86 beating estimates of $0.83 and revenue of $5.44 billion above expectations of $5.36 billion, but simultaneously cut full-year adjusted EPS guidance to $3.28-$3.32 versus consensus of $3.36, and reduced net sales growth expectations to 5.5%-6.5% from 7%-8.5% previously.

The guidance reduction was driven primarily by weakness in its Watchman heart occluder business, with H2 revenue expected to decline mid-to-high single digits year-over-year, alongside competitive pressures in electrophysiology from Medtronic. Argus downgraded the stock from Buy to Hold, while Deutsche Bank cut its target to $60 from $75, UBS to $67 from $74, and RBC to $70 from $85, reflecting broad institutional concern over medium-term growth prospects that has yet to be fully priced in.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114767471?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 23:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114767471","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Boston Scientific Falls 3.03% in Regular Trading, Full-Year Guidance Cut and Multiple Analyst Target Reductions Continue to Weigh","media":"Market Focus","content":"<p><p>On August 5, Boston Scientific declined 3.03% in regular trading, trading at $47.605 per share, with turnover of $182 million.</p><p>The decline reflects continued pressure from the company's lowered full-year guidance and a wave of analyst target price cuts. Boston Scientific reported Q2 adjusted EPS of $0.86 beating estimates of $0.83 and revenue of $5.44 billion above expectations of $5.36 billion, but simultaneously cut full-year adjusted EPS guidance to $3.28-$3.32 versus consensus of $3.36, and reduced net sales growth expectations to 5.5%-6.5% from 7%-8.5% previously.</p><p>The guidance reduction was driven primarily by weakness in its Watchman heart occluder business, with H2 revenue expected to decline mid-to-high single digits year-over-year, alongside competitive pressures in electrophysiology from Medtronic. Argus downgraded the stock from Buy to Hold, while Deutsche Bank cut its target to $60 from $75, UBS to $67 from $74, and RBC to $70 from $85, reflecting broad institutional concern over medium-term growth prospects that has yet to be fully priced in.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Boston Scientific Falls 3.03% in Regular Trading, Full-Year Guidance Cut and Multiple Analyst Target Reductions Continue to Weigh</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Boston Scientific Falls 3.03% in Regular Trading, Full-Year Guidance Cut and Multiple Analyst Target Reductions Continue to Weigh\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 23:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, Boston Scientific declined 3.03% in regular trading, trading at $47.605 per share, with turnover of $182 million.</p><p>The decline reflects continued pressure from the company's lowered full-year guidance and a wave of analyst target price cuts. Boston Scientific reported Q2 adjusted EPS of $0.86 beating estimates of $0.83 and revenue of $5.44 billion above expectations of $5.36 billion, but simultaneously cut full-year adjusted EPS guidance to $3.28-$3.32 versus consensus of $3.36, and reduced net sales growth expectations to 5.5%-6.5% from 7%-8.5% previously.</p><p>The guidance reduction was driven primarily by weakness in its Watchman heart occluder business, with H2 revenue expected to decline mid-to-high single digits year-over-year, alongside competitive pressures in electrophysiology from Medtronic. Argus downgraded the stock from Buy to Hold, while Deutsche Bank cut its target to $60 from $75, UBS to $67 from $74, and RBC to $70 from $85, reflecting broad institutional concern over medium-term growth prospects that has yet to be fully priced in.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"","article_id":"1114767471","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114767471","pubTimestamp":1785943312,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, Boston Scientific declined 3.03% in regular trading, trading at $47.605 per share, with turnover of $182 million.The decline reflects continued pressure from the company's lowered...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"走势警报|波士顿科学常规交易下跌 3.03%，全年指引下调和多位分析师目标下调继续承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"On August 5, Boston Scientific declined 3.03% in regular trading, trading at $47.605 per share, with turnover of $182 million.The decline reflects continued pressure from the company's lowered full-year guidance and a wave of analyst target price cuts. Boston Scientific reported Q2 adjusted EPS of $0.86 beating estimates of $0.83 and revenue of $5.44 billion above expectations of $5.36 billion, but simultaneously cut full-year adjusted EPS guidance to $3.28-$3.32 versus consensus of $3.36, and reduced net sales growth expectations to 5.5%-6.5% from 7%-8.5% previously.The guidance reduction was driven primarily by weakness in its Watchman heart occluder business, with H2 revenue expected to decline mid-to-high single digits year-over-year, alongside competitive pressures in electrophysiology from Medtronic. Argus downgraded the stock from Buy to Hold, while Deutsche Bank cut its target to $60 from $75, UBS to $67 from $74, and RBC to $70 from $85, reflecting broad institutional concern over medium-term growth prospects that has yet to be fully priced in.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114767471","isCrawlerRequest":true}